HIKMA PHARMACEUTICALS PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,858 GBX | +2.48% |
|
+3.91% | +3.91% |
| 11:16am | Hikma Pharmaceuticals backs outlook after making strong start to 2024 | AN |
| 09:16am | Hikma Pharmaceuticals Affirms FY24 Guidance | MT |
Presenter SpeechSigurdur Olafsson (Executives)Hello, everyone. I'm Siggi Olafsson, CEO of Hikm...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows:
- generic injectable products (45.3%);
- brand name drugs (27.5%);
- generic products taken orally (26.7%);
- other (0.5%).
Net sales are distributed geographically as follows: the United Kingdom (0.3%), the United States (56.9%), Middle East and North Africa (34.4%) and other (8.4%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
22.54
USD
Average target price
28.85
USD
Spread / Average Target
+28.02%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +3.91% | 5B | |
| +22.60% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +12.09% | 219B | |
| +6.36% | 199B | |
| -10.06% | 196B | |
| -8.75% | 149B | |
| -5.21% | 146B |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- Transcript : Hikma Pharmaceuticals PLC, 2021 Pre Recorded Earnings Call, Feb 24, 2022
